EP0341104A2

Substituted flavonoid compounds, their salts, their manufacture and medicines containing these materials.

Abstract

Substituted flavonoid compounds of the formula (I): are disclosed. These compounds possess anticancer activity, in particular antipancreatic cancer activity, together with immunomodulatory activity.

EP0341104A2, drawing sheet 1
Sheet 1 of 388

Term

Term ended

Projected expiry passed 6 April 2009, 17.5 years ago.

  1. Priority
  2. Filed
  3. Published
  4. Projected expiry
  5. Today

21 claims: 4 independent, 17 dependent

  1. 1
    A compound of the formula (I):wherein: X is N, O, Se, or S(O) n , wherein n is 0, 1 or 2;R 1 is H;C 1-7 alkyl;naphthyl;phenyl;phenyl substituted by at least one member selected from the group consisting of halogens, C 1-12 alkyl, trifluoromethyl, hydroxyl, C 1-6 alkoxy, (̵C 1-6 -alkylene)̵COOR 10 , nitro, C 1-6 (̵alkyl)̵carboylamino, benzoyl, C 1-6 -(̵alkyl)carboyl, CONR 10 R 11 , (where Rio and R 11 are each independently H or C 1-6 alkyl), NR 10 R 11 , -N=N-NR 10 R 11 , phenyl substituted by at least one halogen atom, phenol, -O(̵C 1-6 alkylene)̵NR 10 R 11 , thiazolyl, and thiazolyl substituted by C 1 - 6 alkyl or amino;or R 1 is pyrridyl;pyrridyl substituted by at least one member selected from the group consisting of C 1-6 alkyls and halogens;trifluoromethyl;benzoyl or benzyl;R 2 is H;phenyl;OH;C 1-3 alkyl;or C 1-3 alkoxy;R 3 and R 4 are each, independently of each other, H;C 1 - 6 alkyl;OH;C 1 - 6 alkoxy;or halogen;Rs is H;C 1-3 alkyl;CN;or COOR 10 R 6 is H;C 1-6 alkyl;OH;(̵C 1-3 alkylene)̵CN;COOR 10 ;-O-CO-(-C 1-6 alkyl);or Rs and R 6 together are a group =CR 10 R 11 , or a group =NOH, or a group =0 or a group =CHR 12 (where R 12 is phenyl, pyrridyl, phenyl substituted by at least one member selected from the group consisting of halogen atoms, trifluoromethyl and C 1-3 alkyls or pyrridyl substituted by at least one member selected from the group consisting of halogen atoms, trifluoromethyl and C 1-3 alkyls);R 7 is H;CHO;COOR 10 ;-CH=CH-COORio;-F(O)(OR 10 R 11 ) 2 ;NR 13 R 14 (where R 13 and R 14 are independently H;phenyl;phenyl substituted by a halogen atom or a C 1-3 alkyl group or a group -COORio, -CO-O-CH(CH 3 )-COOR 10 , morpholinyl, -C(CH 2 0H) 2 (CH 3 ), imidazolinyl, (̵C 1-6 alkylene)̵OH, (̵C 1-6 alkylene)̵COOR 10 , or C 1-3 alkoxy, or wherein R 13 and R 14 together with the nitrogen atom to which they are both bound from an imidazole or a N(̵C 1-3 alkyl)̵piperazinyl);or R 7 is-CO(̵C 1-6 alkyl);-S-(C 1-6 alkyl);-SH;-S-CO(̵C 1-3 alkyl);-S (̵CH 2 )̵ m COOR 10 (with 0 m ≦ 6);-CO-O(̵-C 1-6 alkylene)-NR 10 R 11 ;-O(̵C 1-6 alkylene)̵NR 10 R 11 ;-NR 10 NR 10 R 11 ;C 1 - 6 alkyl;-CONR 10 R 11 ;CSNR 10 R 11 ;thiazolyl;thiazolyl substituted by at least one member selected from the group consisting of -NH 2 , C 1-3 alkyl, phenyl, and COORio;-NH-CO(̵C 1-3 -alkyl);or -(-C 1-3 -alky-Iene)̵CH(NH 2 (COOH);or -CR 5 R 6 R 7 is a group of one of the formula wherein Q is at least one member selected from the group consisting of H;COORio;phenyl;-O(̵C 1-3 -alkylene)̵COOR 10 ;Ci-3 alkyl;-O-CS-NR 10 R 11 ;-O-(̵C 1-3 -alkylene)̵NR1 0R 11 ;OH;C 1-3 alkoxy;and NR 10 R 11 ;or wherein any two of R 3 , R 4 , R 5 , R 6 and R 7 together form a benzene ring;or a benzene ring substituted by (̵C 1-3 -alkylene)̵COOR 10 ;(̵C 1-3 -alkyl)̵OH, COORio, or (̵C 1-3 -alkylene)̵O-CO(̵C 1 - 3 -alkyl);or a naphthalene system;or a naphthalene system substituted by (̵C 1-3 -alkylene)̵COOR 10 , (̵C 1-3 - alky)̵OH, COORio, or (̵C 1-3 -alkylene)̵O-CO(̵C 1-3 -alkyl);and physiologically acceptable salts thereof, with the proviso that when -CR 5 R 6 R 7 is situated at the 8-position of formula (I) and X is O, (i) when R 2 , R 3 , R 4 , R 5 and R 6 are all H and R 7 is CN, R 1 is other than phenyl, 2-thenyl, 3,4-dimethoxy phenyl, 3-methoxy phenyl, para-tolyl, 2-furyl, 2-naphthyl, 4-methoxy phenyl, benzyl, methyl, or cyclohexyl;(ii) when R 2 , Rs, R 4 , Rs and R 5 are all H and R 7 is COOH, R 1 is other than phenyl, 2-thenyl, 3-methoxy phenyl, 3,4-dimethoxy phenyl, 2-furyl, para-tolyl, 2-naphthyl, 4-methoxy phenyl, cyclohexyl, benzyl, or methyl;(iii) when R 2 , R 3 , R 4 , Rs and R 6 are all H and R 7 is -CO-0-CH 2 CH 2 -N(C 2 H 5 ) 2 , R 1 is other than phenyl, 2-thenyl, para-tolyl, or 4-methoxy phenyl;(iv) when R 2 , R 3 , R 4 , R 5 and R 6 are all Hand R 7 is R 1 is other than phenyl;(v) when R 2 , Rs, R 4 , Rs and R 6 are all H and R 7 is -CO-O(̵CH 2 )̵ 3 N(CH 3 ) 2 ;R 7 is other than phenyl;(vi) when R 2 , R 3 , R 4 , R 5 and R 6 are all H and R 7 is -CO-O-C 2 H 5 , R is other than phenyl;(vii) when R 2 , R 3 , R 4 , Rs and R 6 are all H and R 7 is -CO-O-CHs, R 1 is other than phenyl or 2-thenyl;(viii) when R 2 , R 3 , R 4 , R 5 and R 6 are all H and R 7 is -CO-O-Na, R 1 is other than phenyl;(ix) when R 2 , R 3 , R 4 , Rs and R 6 are all H and R 7 is -CO-0-CH 2 CH 2 0H, R 1 is other than phenyl;(x) when R 2 , Rs, R 4 , R 5 and R 6 are all H and R 7 is -CO-NH-CH 2 CH 2 N(C 2 Hs) 2 , R 1 is other than phenyl;(xi) when R 2 , R 4 , Rs and R 6 are all H, R 3 is methyl at the 6-position of formula (I) (6-CH 3 ) and R 7 is COOH, R 1 is other than phenyl;(xii) when R 2 . R 4 , R 5 and R 6 are all H, R 3 is 6-CH 3 and R 7 is COOH 3 , R 1 is other than phenyl;(xiii) when R 2 , R 4 , R 5 and R 6 are all H, R 3 is 6-CH 3 or 6-OCH 3 and R 7 is -CO-0-CH 2 CH 2 -N(CH 2 H 5 ) 2 , R 1 is other than phenyl;(xiv) when R 2 and R 3 are H, R 4 is H or 6-CH 3 , Rs is methyl, R 6 is -COOC 2 H 5 , and R 7 is -COOC 2 H 5 , R 1 is other than phenyl;(xv) when R 2 and R 3 are H, R 4 is H or 6-CH 3 , Rs is H, R 6 is CH 3 and R 7 is COOH, R 1 is other than phenyl;(xvi) when R 2 , R 3 , R 4 and R 5 are all H, R 6 is CH 3 and R 7 is -CO-0-CH 2 CH 2 N(C 2 Hs)2, R 1 is other than phenyl: (xvii) when R 2 , R 3 , R 4 and R 7 are all H, R 5 and R 6 are = O, R 1 is other than phenyl;(xviii) when R 2 , Rs, R 4 , and Rs are all H and -CR 5 R 6 R 7 is -CH=CH-COOH, -CH=CH-COOCH 2 CH 2 N(C 2 H 5 ) 2 , -CH 2 CH(COOC 2 H 5 ) 2 , or-CH 2 CH 2 COOH, R 1 is other than phenyl;(xix) when R 2 and R 3 are both H, R 4 is 6-CH 3 or 6-OCH 3 , R 6 and R 7 are H and Rs is CN, R 1 is other than phenyl;(xx) when R 2 and R 3 are H, R 4 is 6-OCHs or 6-OH, and Rs and R 6 are H and R 7 is COOH, R 1 is other than phenyl;(xxi) when R 2 is phenyl, R 3 and R 4 are H, R 5 and R 6 are = 0, or R 6 is CN or COOH, R 1 is other than phenyl.
  2. 7
    A pharmaceutical composition, comprising a pharmaceutically acceptable carrier and a compound of the formula (I):wherein: X is N, O, Se, or S(O) n , wherein n is 0, 1 or 2;R 1 is H;Ci- 7 alkyl;naphthyl;phenyl;phenyl substituted by at least one member selected from the group consisting of halogens, C 1 - 12 alkyl, trifluoromethyl, hydroxyl, Ci-6 alkoxy, (̵C 1-6 -alkylene)̵COOR 10 , nitro, C 1-6 (̵alkyl)̵carboylamino, benzoyl, C 1-6 (̵alkyl)carboyl, CONR 10 R 11 , (where Rio and R 11 are each independently H or C 1-6 alkyl), NR 10 R 11 , -N=N-NR 10 R 11 , phenyl substituted by at least one halogen atom, phenol, -O(̵C 1-6 alkylene)̵NR 10 R 11 , thiazolyl, and thiazolyl substituted by C 1-6 alkyl or amino;or R 1 is pyrridyl;pyrridyl substituted by at least one member selected from the group consisting of C 1 - 6 alkyls and halogens;trifluoromethyl;benzoyl or benzyl;R 2 is H;phenyl;OH;C 1-3 alkyl;or C 1-3 alkoxy;R 3 and R 4 are each, independently of each other, H;C 1 - 6 alkyl;OH;C 1 - 6 alkoxy;or halogen;R 5 is H;C 1-3 alkyl;CN;or COOR 10 R 6 is H;C 1 - 6 alkyl;OH;(̵C 1-3 alkylene)̵CN;COORio;-O-CO(̵C 1-6 alkyl);or R 5 and R 6 together are a group =CR 10 R 11 , or a group =NOH, or a group =O or a group =CHR 12 (where R 12 is phenyl, pyrridyl, phenyl substituted by at least one member selected from the group consisting of halogen atoms, trifluoromethyl and C 1-3 alkyls or pyrridyl substituted by at least one member selected from the group consisting of halogen atoms, trifluoromethyl and C 1-3 alkyls) ;R 7 is H;CHO;COORio;-CH=CH-COORio;-P(O)(OR 10 R 11 ) 2 ;NR 13 R 14 (where R 13 and R 14 are independently H;phenyl;phenyl substituted by a halogen atom or a C 1-3 alkyl group or a group -COOR 10 , -CO-0-CH(CH 3 )-COORio, morpholinyl, -C(CH 2 0H) 2 (CH 3 ), imidazolinyl, (̵C 1-6 alkylene)̵OH, (̵C 1-6 alkylene)̵COOR 10 , or C 1-3 alkoxy, or wherein R 13 and R 14 together with the nitrogen atom to which they are both bound from an imidazole or a N(̵C 1-3 alkyl)̵ piperazinyl;or R 7 is -CO(̵C 1-6 alkyl);-S-(C 1-6 alkyl);-SH;-S-CO(̵C 1-3 alkyl);-S(̵CH 2 )̵ m COOR 10 (with 0 m ≦ 6);-CO-O(̵C 1-6 alkylene)-NR 10 R 11 ;-O(̵C 1-6 alkylene)̵NR 10 R 11 ;-NR 10 NR 10 R 11 ;C 1 - 6 alkyl;-CONR 10 R 11;CSNR 10 R 11 ;thiazolyl;thiazolyl substituted by at least one member selected from the group consisting of -NH 2 , C 1-a alkyl, phenyl, and COOR 10 ;-NH-CO(̵C 1-3 -alkyl);or (̵C 1-3 -alky- lene)̵CH(NH 2 (COOH);or -CR 5 R 6 R 7 is a group of one of the formulae wherein Q is at least one member selected from the group consisting of H;COOR 10 ;phenyl;-O(̵C 1-3 -alkylene)̵COOR 10 ;Ci-3 alkyl;-O-CS-NR 10 R 11 ;-O(̵C 1-3 -alkylene)̵NR 10R 11 ;OH;C 1-3 alkoxy;and NR 10 R 11 ;or wherein any two of R 3 , R 4 , Rs, R 6 and R 7 together form a benzene ring;or a benzene ring substituted by (̵C 1-3 -alkylene)̵COOR 10 ;(̵C 1-3 -alkyl)̵OH, COORio, or (̵C 1-3 -alkylene)̵O-CO(̵C 1-3 -alkyl);or a naphthalene system;or a naphthalene system substituted by (̵C 1-3 -alkylene)̵COOR 10 , (̵C 1-3 - alky)̵OH, COORio, or (̵C 1-3 -alkylene)̵O-CO(̵-C 1-3 -alkyl);and physiologically acceptable salts thereof, with the proviso that when -CR 5 R 6 R 7 is situated at the 8-position of formula (I) and X is 0, (i) when R 2 , R 3 , R 4 , R 5 and R 6 are all H and R 7 is CN, R 1 is other than phenyl, 2-thenyl, 3,4-dimethoxy phenyl, 3-methoxy phenyl, para-tolyl, 2-furyl, 2-naphthyl, 4-methoxy phenyl, benzyl, methyl, or cyclohexyl;(ii) when R 2 , R 3 , R 4 , R 5 and Rs are all H and R 7 is COOH, R 1 is other than phenyl, 2-thenyl, 3-methoxy phenyl, 3,4-dimethoxy phenyl, 2-furyl, para-tolyl, 2-naphthyl, 4-methoxy phenyl, cyclohexyl, benzyl, or methyl;(iii) when R 2 , R 3 , R 4 , R 5 and R 6 are all H and R 7 is -CO-O-CH 2 CH 2 -N(C 2 H 5 ) 2 , R 1 is other than phenyl, 2-thenyl, para-tolyl, or 4-methoxy phenyl;(iv) when R 2 , R 3 , R 4 , R 5 and R 6 are all H and R 7 is R 1 is other than phenyl;(v) when R 2 , R 3 , R 4 , Rs and R 6 are all H and R 7 is -CO-O(̵OCH 2 )̵ 3 N(CH 3 ) 2 ;R 7 is other than phenyl;(vi) when R 2 , R3, R4, R 5 and R 6 are all H and R 7 is -CO-O-C 2 H 5 , R 1 is other than phenyl;(vii) when R 2 , R 3 , R 4 , Rs and R 6 are all H and R 7 is -CO-O-CH 3 , R 1 is other than phenyl or 2-thenyl;(viii) when R 2 , Rs, R 4 , Rs and R 6 are all H and R 7 is -CO-O-Na, R 1 is other than phenyl;(ix) when R 2 , R 3 , R 4 , R 5 and R 6 are all H and R 7 is -CO-O-CH 2 CH 2 OH, R 1 is other than phenyl;(x) when R 2 , R 3 , R 4 , Rs and R 6 are all H and R 7 is -CO-NH-CH 2 CH 2 N(C 2 H 5 ) 2 , R 1 is other than phenyl;(xi) when R 2 , R 4 , R 5 and R 6 are all H, R 3 is methyl at the 6-position of formula (I) (6-CH 3 ) and R 7 is COOH, R 1 is other than phenyl;(xii) when R 2 , R 4 , R 5 and R 6 are all H, R 3 is 6-CH 3 and R 7 is COOH 3 , R 1 is other than phenyl;(xiii) when R 2 , R 4 , R 5 and R 6 are all H, R 3 is 6-CHs or 6-OCH 3 and R 7 is -CO-O-CH 2 CH 2 -N(CH 2 H 5 ) 2 , R 1 is other than phenyl;(xiv) when R 2 and R 3 are H, R 4 is H or 6-CH 3 , R 5 is methyl, R 6 is -COOC 2 H 5 , and R 7 is -COOC 2 H 5 , R 1 is other than phenyl;(xv) when R 2 and R 3 are H, R 4 is H or 6-CH 3 , Rs is H, R 6 is CH 3 and R 7 is COOH, R 1 is other than phenyl;(xvi) when R 2 , Rs, R 4 and R 5 are all H, R 6 is CH 3 and R 7 is -CO-0-CH 2 CH 2 N(C 2 Hs) 2 , Ri is other than phenyl;(xvii) when R 2 , R 3 , R 4 and R 7 are all H, Rs and R 6 are =O, R 1 is other than phenyl;(xviii) when R 2 , R 3 , R 4 , and R 5 are all H and -CR 5 R 6 R 7 is CH=CH-COOH, -CH=CH-COOCH 2 CH 2 N(C 2 H 5 ) 2 , -CH 2 CH(COOC 2 H 5 ) 2 , or -CH 2 CH 2 COOH, R 1 is other than phenyl;(xix) when R 2 and R 3 are both H, R 4 is 6-CH 3 or 6-OCH 3 , R 6 and R 7 are H and R 5 is CN, R 1 is other than phenyl;(xx) when R 2 and R 3 are H, R 4 is 6-OCH 3 or 6-OH, and R 5 and R 6 are H and R 7 is COOH, R 1 is other than phenyl;(xxi) when R 2 is phenyl, R 3 and R 4 are H, R 5 and R 6 are = 0, or R 6 is CN or COOH, R 1 is other than phenyl.
  3. 11
    13. A method for treating cancer in a patient in need thereof, comprising administering to said patient a compound of the formula (I):wherein: X is N, O, Se, or S(O) n , wherein n is 0,1 or 2;R 1 is H;C 1-7 alkyl;naphthyl;phenyl;phenyl substituted by at least one member selected from the group consisting of halogens, C 1-12 alkyl, trifluoromethyl, hydroxyl, C 1-6 alkoxy, -(C 1-6 -alkylene)-COOR 10 , nitro, C 1-6 -(alkyl)-carboylamino, benzoyl, C 1-6 -(alkyl)carboyl, CONR 10 R 11 , (where Rio and R 11 are each independently H or C 1-6 alkyl), NR 10 R 11 , -N=N-NR 10 R 11 , phenyl substituted by at least one halogen atom, phenol, -O-(C 1-6 alkylene)-NR 10 R 11 , thiazolyl, and thiazolyl substituted by C 1 - 6 alkyl or amino;or R 1 is pyrridyl;pyrridyl substituted by at least one member selected from the group consisting of C 1-6 alkyls and halogens;trifluoromethyl;benzoyl or benzyl;R 2 is H;phenyl;OH;C 1-3 alkyl;or C 1-3 alkoxy;R 3 and R 4 are each, independently of each other, H;C 1-6 alkyl;OH;C 1-6 alkoxy;or halogen;R 5 is H;Ci-3 alkyl;CN;or COOR 10 R 6 is H;C 1-6 alkyl;OH;-(C 1-3 alkylene)-CN;COOR 10 ;-O-CO-(C 1-6 alkyl);or Rs and R 6 together are a group =CR 10 R 11 , or a group =NOH, or a group =0 or a group =CHR 12 (where R 12 is phenyl, pyrridyl, phenyl substituted by at least one member selected from the group consisting of halogen atoms, trifluoromethyl and C 1-3 alkyls or pyrridyl substituted by at least one member selected from the group consisting of halogen atoms, trifluoromethyl and C 1-3 alkyls);R 7 is H;CHO;COORio;-CH=CH-COORi o ;-P(O)(OR 10 R 11 ) 2 ;NR 13 R 14 (where R 13 and R 14 are independently H;phenyl;phenyl substituted by a halogen atom or a C 1-3 alkyl group or a group -COOR 10 , -CO-0-CH(CH 3 )-COORio, morpholinyl, -C(CH 2 0H) 2 (CH 3 ), imidazolinyl, -(C 1-6 alkylene)-OH, -(C 1-6 alkylene)-COOR 10 , or C 1-3 alkoxy, or wherein R 13 and R 14 together with the nitrogen atom to which they are both bound from an imidazole or a N-(C 1-3 alkyl )-piperazinyl);or R 7 is -CO-(C 1-6 alkyl);-S-(Ci- 6 alkyl);-SH;-S-CO-(C 1-3 alkyl);-S-(CH 2 ) m - COOR 10 (with 0 m ≦ 6);-CO-O-(C 1-6 alkylene)-NR 10 R 11 ;-O-(C 1-6 alkylene)-NR 10 R 11 ;-NR 10 NR 10 R 11 ;C 1 - 6 alkyl;-CONR 10 R 11 ;-CSNR 10 R 11 ;thiazolyl;thiazolyl substituted by at least one member selected from the group consisting of -NH 2 , C 1-3 alkyl, phenyl, and COOR 10 ;-NH-CO-(C 1-3 -alkyl);or -(C 1-3 -alkylene)-CH(NH 2 (COOH);or -CR 5 R 6 R 7 is a group of one of the formulae wherein Q is at least one member selected from the group consisting of H;COOR 10 ;phenyl;-O-(C 1-3 -alkylene)-COOR 10 ;C 1 - 3 alkyl;-O-CS-NR 10 R 11 ;O-(C 1-3 -alkylene)-NR 10R11 ;OH;C 1-3 alkoxy;and NR 10 R 11 ;or wherein any two of R 3 , R 4 , Rs, R 6 and R 7 together form a benzene ring;or a benzene ring substituted by -(C 1-3 -alkylene)-COOR 10 ;-(C 1-3 -alkyl)-OH, COORio, or -(C 1-3 -alkylene)-O-CO-(C 1-3 alkyl);or a naphthalene system;or a naphthalene system substituted by -(C 1-3 -alkylene)-COOR 10 , -(C 1-3 alky)-OH, COORio, or -(C 1-3 -alkylene)-O-CO-(C 1-2 -alkyl);and physiologically acceptable salts thereof, with the proviso that when -CR 5 R 6 R 7 is situated at the 8-position of formula (I) and X is 0, (i) when R 2 , R 3 , R 4 , Rs and R 6 are all H and R 7 is CN, R 1 is other than phenyl, 2-thenyl, 3,4-dimethoxy phenyl, 3-methoxy phenyl, para-tolyl, 2-furyl, 2-naphthyl, 4-methoxy phenyl, benzyl, methyl, or cyclohexyl;(ii) when R 2 , R 3 , R 4 , R 5 and R 5 are all H and R 7 is COOH, R 1 is other than phenyl, 2-thenyl, 3-methoxy phenyl, 3,4-dimethoxy phenyl, 2-furyl, para-tolyl, 2-naphthyl, 4-methoxy phenyl, cyclohexyl, benzyl, or methyl;(iii) when R 2 , R 3 , R 4 , R 5 and R 6 are all H and R 7 is -CO-O-CH 2 CH 2 -N(C 2 H 5 ) 2 , Ri is other than phenyl, 2-thenyl, para-tolyl, or 4-methoxy phenyl;(iv) when R 2 , R 3 , R 4 , R 5 and R 6 are all H and R 7 is R 1 is other than phenyl;(v) when R 2 , Rs, R 4 , R 5 and R 6 are all H and R 7 is -CO-O-(CH 2 )- 3 N(CH 3 ) 2 ;R 7 is other than phenyl;(vi) when R 2 , R 3 , R 4 , Rs and R 6 are all H and R 7 is -CO-O-C 2 H 5 , R 1 is other than phenyl;(vii) when R 2 , R 3 , R 4 , R 5 and R 6 are all H and R 7 is -CO-O-CH 3 , R 1 is other than phenyl or 2-thenyl;(viii) when R 2 , R 3 , R 4 , R 5 and R 6 are all H and R 7 is -CO-O-Na, R 1 is other than phenyl;(ix) when R 2 , R 3 , R 4 , Rs and R 6 are all H and R 7 is -CO-0-CH 2 CH 2 0H, R 1 is other than phenyl;(x) when R 2 , R 3 , R 4 , R 5 and R 6 are all H and R 7 is -CO-NH-CH 2 CH 2 N(C 2 H 5 ) 2 , R 1 is other than phenyl;(xi) when R 2 , R 4 , R 5 and R 6 are all H, R 3 is methyl at the 6-position of formula (I) (6-CHs) and R 7 is COOH, R 1 is other than phenyl;(xii) when R 2 , R 4 , R 5 and R 6 are all H, R 3 is 6-CH 3 and R 7 is COOH 3 , R 1 is other than phenyl;(xiii) when R 2 , R 4 , R 5 and R 6 are all H, R 3 is 6-CH 3 or 6-OCH 3 and R 7 is -CO-O-CH 2 CH 2 -N(CH 2 H 5 ) 2 , R 1 is otherthan phenyl;(xiv) when R 2 and R 3 are H, R 4 is H or 6-CHs, R 5 is methyl, R 6 is -COOC 2 H 5 , and R 7 is -COOC 2 H 5 , R 1 is other than phenyl;(xv) when R 2 and R 3 are H, R 4 is H or 6-CH 3 , R 5 is H, R 6 is CH 3 and R 7 is COOH, R 1 is other than phenyl;(xvi) when R 2 , R 3 , R 4 and Rs are all H, R 6 is CH 3 and R 7 is -CO-O-CH 2 CH 2 N(C 2 H 5 ) 2 , R 1 is other than phenyl;(xvii) when R 2 , R 3 , R 4 and R 7 are all H, R 5 and R 6 are =O, R 1 is other than phenyl;(xviii) when R 2 , R 5 , R 4 , and R 5 are all H and -CR 5 R 6 R 7 is -CH=CH-COOH, -CH= CH -COOCH 2 CH 2 N(C 2 H 5 ) 2 , -CH 2 CH(COOC 2 H 5 ) 2 , or -CH 2 CH 2 COOH, R 1 is other than phenyl;(xix) when R 2 and R 3 are both H, R 4 is 6-CH 3 or 6-OCH 3 , R 6 and R 7 are H and R 5 is CN, R 1 is other than phenyl;(xx) when R 2 and R 3 are H, R 4 is 6-OCHs or 6-OH, and Rs and R 6 are H and R 7 is COOH, R 1 is other than phenyl;(xxi) when R 2 is phenyl, R 3 and R 4 are H, R 5 and R 6 are = 0, or R 6 is CN or COOH, R 1 is other than phenyl.
  4. 17
    19. A method for treating a patient in need thereof with a compound possessing immunomodulatory properties, comprising administering to said patient a compound of the formula (I):wherein: X is N, O, Se, or S(O) n , wherein n is 0, 1 or 2;R 1 is H;Ci-7 alkyl;naphthyl;phenyl;phenyl substituted by at least one member selected from the group consisting of halogens, C 1-12 alkyl, trifluoromethyl, hydroxyl, C 1 - 6 alkoxy, -(C 1-6 -alkyleneCOOR 10 , nitro, C 1-6 -(alkyl)-carboylamino, benzoyl, C 1-6 -(alkyl)carboyl, CONR 10 R 11 , (where Rio and R 11 are each independently H or C 1 - 6 alkyl), NR 10 R 11 , -N=N-NR 10 R 10 , phenyl substituted by at least one halogen atom, phenol, -O-(C 1-6 alkylene)-NR 10 R 11 , thiazolyl, and thiazolyl substituted by C 1 - 6 alkyl or amino;or R 1 is pyrridyl;pyrridyl substituted by at least one member selected from the group consisting of C 1-6 alkyls and halogens;trifluoromethyl;benzoyl or benzyl;R 2 is H;phenyl;OH;C 1-3 aikyl;or C 1-3 alkoxy;R 3 and R 4 are each, independently of each other, H;C 1 - 6 alkyl;OH;C 1 - 6 alkoxy;or halogen;R 5 is H;C 1 - 3 alkyl;CN;or COOR 10 R 6 is H;Ci-6 alkyl;OH;-(C 1-3 alkylene)-CN;COOR 10 ;-O-CO-(C 1-6 alkyl);or R 5 and R 6 together are a group =CR 10 R 11 , or a group = NOH, or a group =O or a group =CHR 12 (where R 12 is phenyl, pyrridyl, phenyl substituted by at least one member selected from the group consisting of halogen atoms, trifluoromethyl and C 1-3 alkyls or pyrridyl substituted by at least one member selected from the group consisting of halogen atoms, trifluoromethyl and Ci-3 alkyls);R 7 is H;CHO;COORio;-CH=CH-COORio;-P(O)(OR 10 R 11 ) 2 ;NR 13 R 14 (where R 13 and R 14 are independently H;phenyl;phenyl substituted by a halogen atom or a C 1-3 alkyl group or a group -COORio, -CO-O-CH(CH 3 )-COOR 10 , morpholinyl, -C(CH 2 OH) 2 (CH 3 ), imidazolinyl, -(C 1-6 alkylene)-OH, -(C 1-6 alkylene)-COOR 10 , or Ci- 3 alkoxy, or wherein R 13 and R 14 together with the nitrogen atom to which they are both bound from an imidazole or a N-(C 1-3 alkyl )-piperazinyl);or R 7 is -CO-(C 1-6 alkyl);-S-(C 1-6 alkyl);-SH;-S-CO-(C 1-3 alkyl);-S-(CH 2 ) m - COORio (with 0 m ≦ 6);-CO-O-(C 1-6 alkylene)-NR 10 R 11 ;-O-(C 1-6 alkylene)-NR 10 R 11 ;-NR 10 NR 10 R 11 ;C 1 - 6 alkyl;-CONR 10 R 11 ;-CSNR 10 R 11 ;thiazolyl;thiazolyl substituted by at least one member selected from the group consisting of -NH 2 , C 1-3 alkyl, phenyl, and COOR 10 ;NH-CO-(C 1-3 -alkyl);or -(C 1-3 -alkylene)-CH(NH 2 (COOH);or -CR 5 R 6 R 7 is a group of one of the formulae wherein Q is at least one member selected from the group consisting of H;COOR 10 ;phenyl;-O-(C 1-3 -alkylene)-COOR 10 ;C 1-3 alkyl;-O-CS-NR 10 R 11 ;-O-(C 1-3 -alkylene)-NR 10R11 ;OH;C 1-3 alkoxy;and NR 10 R 11 ;or wherein any two of Rs, R 4 , R 5 , R 6 and R 7 together form a benzene ring;or a benzene ring substituted by -(C 1-3 -alkylene)-COOR 10 ;-(C 1-3 -alkyl)-OH, COOR 10 , or -(C 1-3 -alkylene)-O-CO-(C 1-3 -alkyl);or a naphthalene system;or a naphthalene system substituted by -(C 1-3 -alkylene)-COOR 10 , -(C 1-3 alky)-OH, COORio, or -(C 1-3 -alkylene)-O-CO-(C 1-3 -alkyl);and physiologically acceptable salts thereof, with the proviso that when -CR 5 R 6 R 7 is situated at the 8-position of formula (I) and X is 0, (i) when R 2 , R 3 , R 4 , Rs and R 6 are all H and R 7 is CN, R 1 is other than phenyl, 2-thenyl, 3,4-dimethoxy phenyl, 3-methoxy phenyl, para-tolyl, 2-furyl, 2-naphthyl, 4-methoxy phenyl, benzyl, methyl, or cyclohexyl;(ii) when R 2 , R 3 , R 4 , R 5 and R 5 are all H and R 7 is COOH, R 1 is other than phenyl, 2-thenyl, 3-methoxy phenyl, 3,4-dimethoxy phenyl, 2-furyl, para-tolyl, 2-naphthyl, 4-methoxy phenyl, cyclohexyl, benzyl, or methyl;(iii) when R 2 , R 3 , R 4 , R 5 and R 6 are all H and R 7 is -CO-O-CH 2 CH 2 -N(C 2 H 5 ) 2 , R 1 is other than phenyl, 2-thenyl, para-tolyl, or 4-methoxy phenyl;(iv) when R 2 , R 3 , R 4 , R 5 and R 6 are all H and R 7 is R 1 is other than phenyl;(v) when R 2 , R 3 , R 4 , Rs and R 6 are all H and R 7 is -CO-O-(CH 2 ) 3 -N(CH 3 ) 2 ;R 7 is other than phenyl;(vi) when R 2 , R 3 , R 4 , Rs and R 6 are all H and R 7 is -CO-O-C 2 H 5 , R 1 is other than phenyl;(vii) when R 2 , R 3 , R 4 , Rs and R 6 are all H and R 7 is -CO-O-CH 3 , R 1 is other than phenyl or 2-thenyl;(viii) when R 2 , R 3 , R 4 , R 5 and R 6 are all H and R 7 is -CO-O-Na, R 1 is other than phenyl;(ix) when R 2 , Rs, R 4 , Rs and R 6 are all H and R 7 is -CO-0-CH 2 CH 2 0H, R 1 is other than phenyl;(x) when R 2 , R 3 , R 4 , R 5 and R 6 are all H and R 7 is -CO-NH-CH 2 CH 2 N(C 2 H 5 ) 2 , R 1 is other than phenyl;(xi) when R 2 , R 4 , Rs and R 6 are all H, R 3 is methyl at the 6-position of formula (I) (6-CH 3 ) and R 7 is COOH, R 1 is other than phenyl;(xii) when R 2 , R 4 , R 5 and R 6 are all H, R 3 is 6-CH 3 and R 7 is COOH 3 , R 1 is other than phenyl;(xiii) when R 2 , R 4 , Rs and R 6 are all H, R 3 is 6-CH 3 or 6-OCH 3 and R 7 is -CO-0-CH 2 CH 2 -N(CH 2 H 5 ) 2 , R 1 is other than phenyl;(xiv) when R 2 and R 3 are H, R 4 is H or 6-CH 3 , R 5 is methyl, R 6 is -COOC 2 H 5 , and R 7 is -COOC 2 H 5 , R 1 is other than phenyl;(xv) when R 2 and R 3 are H, R 4 is H or 6-CH 3 , Rs is H, R 6 is CH 3 and R 7 is COOH, R 1 is other than phenyl;(xvi) when R 2 , R 3 , R 4 and Rs are all H, R 6 is CH 3 and R 7 is -CO-O-CH 2 CH 2 N(C 2 H 5 ) 2 , R 1 is other than phenyl;(xvii) when R 2 , R 3 , R 4 and R 7 are all H, R 5 and R 6 are =O, R 1 is other than phenyl;(xviii) when R 2 , R 3 , R 4 , and Rs are all H and -CR 5 R 6 R 7 is -CH=CH-COOH, -CH=CH-COOCH 2 CH 2 N(C 2 Hs) 2 , -CH 2 CH(COOC 2 H 5 ) 2 , or-CH2CH2COOH, R 1 is other than phenyl;(xix) when R 2 and R 3 are both H, R 4 is 6-CH 3 or 6-OCH 3 , R 6 and R 7 are H and R 5 is CN, R 1 is other than phenyl;(xx) when R 2 and R 3 are H, R 4 is 6-OCH 3 or 6-OH, and Rs and R 6 are H and R 7 is COOH, R 1 is other than phenyl;(xxi) when R 2 is phenyl, R 3 and R 4 are H, R 5 and R 6 are =O, or R 6 is CN or COOH, R 1 is other than phenyl.